Hims & Hers warns its supply of compounded weight loss drugs could be 'constrained'-March 2024-www.financetom.com

Hims & Hers warns its supply of compounded weight loss drugs could be 'constrained'

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Hims & Hers warns its supply of compounded weight loss drugs could be 'constrained'

Feb 24, 2025 2:38 PM

Feb 24 (Reuters) - Hims & Hers said the U.S.

FDA's decision that the shortage of Novo Nordisk's

weight-loss and diabetes drugs had been resolved could constrain

the telehealth firm's ability to continue providing access to

compounded versions of the drugs on its platform once current

inventory has been sold.

(Reporting by Sneha S K in Bengaluru)

Previous page： Zevia Receives NYSE Noncompliance Notice Next page： First Foundation Gets $228 Million Investment from Investor Group

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Zevia Receives NYSE Noncompliance Notice

Jul 2, 2024

05:57 PM EDT, 07/02/2024 (MT Newswires) -- Zevia PBC ( ZVIA ) said Tuesday it received a noncompliance notice from the New York Stock Exchange for not meeting the minimum share price for its class A common stock. The company is considering all available options to remain listed on the bourse. It is preparing a response to the NYSE notice...

First Foundation Gets $228 Million Investment from Investor Group

Jul 2, 2024

05:53 PM EDT, 07/02/2024 (MT Newswires) -- First Foundation ( FFWM ) said Tuesday affiliates of Fortress Investment Group, Canyon Partners, Strategic Value Bank Partners, North Reef Capital are investing up to $228 million. Fortress affiliates will invest $115 million, Canyon Partners $46 million, Strategic Value Bank Partners $22 million, and North Reef Capital $22 million, with other investors contributing...

PolyPid Registers $200 Million Ordinary Stock

Jul 2, 2024

05:52 PM EDT, 07/02/2024 (MT Newswires) -- Polypid ( PYPD ) plans to sell up to $200 million of its ordinary shares from time to time, according to a preliminary prospectus filed late Tuesday. The company expects to use proceeds for general corporate purposes, including funding operations, capital projects and business development. Price: 3.9800, Change: -0.02, Percent Change: -0.50 ...

Scilex Holding Unit Semnur Pharmaceuticals, Denali Capital Acquisition Propose Merger

Jul 2, 2024

05:58 PM EDT, 07/02/2024 (MT Newswires) -- Scilex Holding ( SCLX ) unit Semnur Pharmaceuticals and Denali Capital Acquisition ( DECA ) , a blank-check company, said they signed a letter of intent for a proposed business combination. The deal translates into an equity value of Semnur of up to $2 billion, subject to certain adjustments. The expected cash on...